Navigation Links
Scripps research team blocks bacterial communication system to prevent deadly staph infections
Date:10/30/2007

LA JOLLA, CALIFORNIA, OCT. 30, 2007 -- In hopes of combating the growing scourge of antibiotic-resistant bacteria, in particular drug-resistant staph bacteria, a team of scientists from the Scripps Research Institute has designed a new type of vaccine that could one day be used in humans to block the onset of infection. The advantage of the new vaccine is that it would work not only on current bacterial resistant stains but also would not induce the potential for new bacterial resistance because, rather than killing bacterial cells, it blocks their communication system, preventing the shift from harmless to virulent, thus allowing the bodys natural defenses to combat the bacteria.

The work was published in the October 29 issue of the journal Chemistry and Biology.

Staph and other infections are becoming increasingly deadly because many strains of the bacteria that cause disease develop resistance to the array of antibiotics used to control them. A Centers for Disease Control (CDC) report released last week estimated that more than 94,000 Americans were infected in 1995 by a drug-resistant staph superbug called methicillin-resistant Staphylococcus aureus (MRSA), and more than 18,000 Americans died that year during hospital stays involving this type of infection.

The bacterial infection process is dependent on a sort of chemical conversation between individual bacterial cells, referred to as quorum sensing. In their free-living state, bacteria are typically easy to kill and non-virulent. The shift to virulence is dependent on small molecules emitted by bacteria known as autoinducers, because bacteria sense when concentrations of these autoinducers are high enough to suggest a large number of other bacteria are present.

Bacteria basically sense they have enough of their buddies around to allow them to say, 'OK, we're in a favorable environment to start turning on certain genes,' says team leader Professor Kim Janda, director of the Worm Institute for Research and Medicine at Scripps Research and a vaccine expert who has worked on the development of vaccines for obesity and drugs of addiction, among other problems.

The genes turned on by quorum sensing may encode proteins harmless to their hosts, but they can also code for the toxins and other products arising from bacterial infections that cause disease. Sequestering autoinducers in some way could therefore block quorum sensing and, hence, the establishment of infections. The scientists predict that such a strategy would not lead to resistance in bacteria because it wouldn't kill the cells. Bacteria would simply remain in an inert form because they would be tricked into thinking not enough other cells were present to shift into their virulent mode.

Bacteria use a variety of genetic mechanisms in quorum sensing. The Scripps Research team focused on Gram-positive bacteria, whose quorum sensing is controlled by four basic types of autoinducers tied to a circuit known as the accessory gene regulator. Based on the known structure of one of these autoinducers, the team designed a molecule known as a hapten that, when conjugated with specific proteins using well-established procedures, induces the production of antibodies by the immune system.

The Janda group intentionally designed the hapten to be stable enough to work well as a potential treatment, and ultimately chose to pursue work with one of the haptens that proved the most stable. Past research by other groups has involved successfully blocking quorum sensing using molecules that essentially plug the keyholes on cell surfaces that allow bacteria to sense autoinducers, but such strategies have been hampered by the inherent instabilities of the molecules involved.

Next, the team isolated and studied the antibodies produced in mice injected with the hapten, called AP4. Subsequent experiments revealed that one of these antibodies in particular, when administered to mice infected with Staphylococcus aureus, was highly effective at binding with and sequestering the targeted autoinducer, and to a lesser extent with a second autoinducer. This activity proved to effectively block quorum sensing and infection in the mice.

Resistance to S. aureus, a common form of Staph infection has become a major concern in hospitals, and, as the recent CDC report indicates, outside of medical settings as well. As a result, says Janda, I think the impact of this approach could be really huge, because our approach side steps the resistance problem with common antibiotic treatments.

Janda says the antibody AP4-24H11 could one day be given to humans as a passive vaccine to block infections as it did in mice. The AP4 hapten could also be applied as an active vaccine that would induce production of antibodies to block quorum sensing. He says such vaccines could, for instance, be given to patients entering the hospital for surgery to prevent infection by Staph bacteria. This would not, however, probably be an effective treatment against infections that have already progressed, because in such cases the damage from quorum sensing would already have been done.

Janda and his colleagues, including Junguk Park, Gunnar Kaufmann and Richard Ulevitch, chairman of the Scripps Research Department of Immunology, are already working to design related haptens that will induce antibodies effective against all the autoinducers used by Gram-positive bacteria, which might one day be administered as a vaccine cocktail to prevent infection by a wide range of bacteria. The group is seeking a pharmaceutical partner to fund further tests with AP4 and AP4-24H11 in animal models and, if all goes well, to carry a vaccine through human clinical trials.


'/>"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
Source:Eurekalert

Related biology news :

1. Scripps scientists find potential for catastrophic shifts in Pacific ecosystems
2. To Stop Evolution: New Way Of Fighting Antibiotic Resistance Demonstrated By Scripps Scientists
3. Scripps research scientists identify infertility molecule
4. Scripps research scientists solve structure of a critical innate immune system protein
5. New Scripps Oceanography project to study sediments and ecosystem restoration in Venice lagoon
6. Scripps Research study reveals new activation mechanism for pain sensing channel
7. Scripps research team discovers a chemical pathway that causes mice to overeat and gain weight
8. Scripps research study reveals structural dynamics of single prion molecules
9. Scripps research study shows humans and plants share common regulatory pathway
10. Scripps research team sheds light on long-sought cold sensation gene
11. Researchers discover way to make cells in the eye sensitive to light
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:6/27/2016)... Research and Markets has announced the addition of the "Biometrics ... The report forecasts the biometrics market ... CAGR of 12.28% during the period 2016-2020. The ... inputs from industry experts. The report covers the market landscape and ... a discussion of the key vendors operating in this market. ...
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... HAMILTON, Bermuda , Dec. 5, 2016 ... leading clinical-stage biopharmaceutical company focused on the treatment of ... of intepirdine for the treatment of Alzheimer,s disease will ... Disease (CTAD) Meeting on Friday, December 9, 2016 in ... CTAD will show results of both simple and complex ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... to soon resume cervical and lumbar disc production, company President, Jake Lubinski will ... who are implanting the AxioMed disc in Cologne and Karlsruhe to discuss the ...
(Date:12/5/2016)... NxGen MDx announced today that it brought its NxGen Informed ... been able to improve customer service through shortened turnaround times and at ... , CEO of NxGen MDx. ... A decrease in turnaround times by ... job opportunities at the Grand Rapid headquarters. The NxGen Informed ...
(Date:12/4/2016)... ... December 02, 2016 , ... A proposed five-year extension ... federally funded research and development is welcome news for the photonics community, say ... , As part of the National Defense Authorization Act (NDAA) compromise agreement finalized ...
Breaking Biology Technology: